Market Closed -
Other stock markets
|
Pre-market 09:16:42 am | |||
5.21 USD | -0.76% | 5.16 | -0.96% |
May. 20 | Jefferies lowers target for Evotec to 16 Euro - 'Buy' | DP |
May. 20 | EVOTEC : Jefferies maintains a Buy rating | ZD |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 46% by 2026.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-55.58% | 1.86B | - | ||
+41.79% | 54.04B | B- | ||
+45.94% | 41.96B | A | ||
-0.56% | 41.92B | B | ||
-7.20% | 28.35B | C | ||
+12.59% | 26.35B | B- | ||
-21.51% | 19B | B | ||
+6.92% | 13B | B+ | ||
+29.60% | 12.28B | C+ | ||
+24.91% | 12.19B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EVT Stock
- EVO Stock
- Ratings Evotec SE